# Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

> **NCT03984357** · PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 152 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** PD-1 blocking antibody
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **RADIATION:** Intensity-modulated radiotherapy

## Key facts

- **NCT ID:** NCT03984357
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-16
- **Primary completion:** 2024-04-30
- **Final completion:** 2025-03-30
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2025-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03984357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03984357, "Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03984357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*